Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Background Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybri...

Полное описание

Библиографические подробности

Главные авторы:	Lars Möllgård, Leonie Saft, Marianne Bach Treppendahl, Ingunn Dybedal, Jan Maxwell Nørgaard, Jan Astermark, Elisabeth Ejerblad, Hege Garelius, Inge Høgh Dufva, Monika Jansson, Martin Jädersten, Lars Kjeldsen, Olle Linder, Lars Nilsson, Hanne Vestergaard, Anna Porwit, Kirsten Grønbæk, Eva Hellström Lindberg
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Ferrata Storti Foundation 2011-07-01
Серии:	Haematologica
Online-ссылка:	https://haematologica.org/article/view/6025
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!